Choi Mihong, Lee Youngjoo, Moon Sung Ho, Han Ji-Youn, Kim Heung Tae, Lee Jin Soo
Department of Internal Medicine, National Cancer Center, Goyang, Korea.
Department of Internal Medicine, National Cancer Center, Goyang, Korea; Center for Lung Cancer, National Cancer Center, Goyang, Korea.
Clin Lung Cancer. 2017 Jan;18(1):77-84. doi: 10.1016/j.cllc.2016.06.012. Epub 2016 Jun 29.
Prophylactic cranial irradiation (PCI) was reported to offer survival benefits in patients with limited stage small-cell lung cancer (LS-SCLC). However, earlier studies did not routinely use positron emission tomography (PET) as part of the initial evaluation, thereby reducing the accuracy of tumor staging. We examined the effect of more accurate staging with PET on the role of PCI in patients with LS-SCLC.
We retrospectively collected data from 280 patients with LS-SCLC who had objective responses after combined chemoradiotherapy between 2001 and 2013. The outcomes of PCI were analyzed after stratifying the patients according to whether or not the initial staging included PET imaging.
The risk of brain metastasis as the first site of relapse was lower in patients who received PCI than in those who did not, only in patients without initial PET imaging (13.3% vs. 37.0%; P = .020), but not in patients with initial PET imaging (34.3% vs. 41.1%; P = .243). There was no survival difference between subgroups who received PCI or not (5-year survival rates, 34.8% vs. 34.1%; P = .938). Patients who had initial staging evaluation with PET achieved long-term survival even without PCI (5-year survival rates, 38.3% with PCI, 38.6% without PCI).
The role of PCI needs to be critically reassessed in LS-SCLC patients whose initial staging evaluation included PET because the benefit of PCI was not apparent for them.
据报道,预防性颅脑照射(PCI)可使局限期小细胞肺癌(LS-SCLC)患者受益。然而,早期研究并未常规使用正电子发射断层扫描(PET)作为初始评估的一部分,从而降低了肿瘤分期的准确性。我们研究了PET更准确分期对PCI在LS-SCLC患者中作用的影响。
我们回顾性收集了2001年至2013年间280例接受放化疗后有客观反应的LS-SCLC患者的数据。根据初始分期是否包括PET成像对患者进行分层后,分析PCI的结果。
仅在未进行初始PET成像的患者中,接受PCI的患者脑转移作为首次复发部位的风险低于未接受PCI的患者(13.3%对37.0%;P = 0.020),而在进行初始PET成像的患者中则无此差异(34.3%对41.1%;P = 0.243)。接受PCI与未接受PCI的亚组之间生存率无差异(5年生存率,34.8%对34.1%;P = 0.938)。进行初始PET分期评估的患者即使未接受PCI也能实现长期生存(5年生存率,接受PCI的为38.3%,未接受PCI的为38.6%)。
对于初始分期评估包括PET的LS-SCLC患者,PCI的作用需要重新进行严格评估,因为PCI对他们的益处并不明显。